26 May 2013
Keywords: first, approval, sb, teveten, germany, smithkline, beecham
Article | 09 June 1997
SmithKline Beecham's angiotensin II receptor antagonist, Teveten(eprosartan), for the treatment of hypertension, has been approved in
its first market, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
9 June 1997
24 May 2013
© 2013 thepharmaletter.com